A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

NCT00136591 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

87

Enrollment

OTHER

Sponsor class

Stopped An arm closed due to lack of efficacy

Conditions

Follicular Lymphoma

Interventions

DRUG: Bortezomib
DRUG: Bortezomib

Sponsor

Lymphoma Study Association

Collaborators

[object Object]